9 active not recruiting, 2 completed, 2 recruiting, 1 withdrawn. 6 Phase 1, 6 Phase 2, 2 Early Phase 1, 2 Phase 3, 1 Not applicable.
Follow Primary Peritoneal High Grade Serous Adenocarcinoma: new trials by email Literature Review of Primary Peritoneal High Grade Serous Adenocarcinoma trials Research Report on Primary Peritoneal High Grade Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Uterine Lavage to Detect Ovarian Cancer Risk Uterine Lavage, Archive Sample, Survey Administration - BRCA Hereditary Ovarian Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Not applicable | Recruiting | University of Washington | 75 | 2026-09-03 | 2026-09-14 |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 3 | Recruiting | NRG Oncology | 880 | 2025-03-12 | 2026-11-09 |
| Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer Biopsy Procedure, Carboplatin, Ipatasertib - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 25 | 2022-09-08 | 2026-09-22 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Biospecimen Collection, Computed Tomography, Echocardiography Test - Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2020-05-07 | 2026-07-20 |
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 61 | 2019-12-04 | 2026-08-26 |
| Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery Chemotherapy, Olaparib, Therapeutic Conventional Surgery - BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2019-06-07 | 2026-08-12 |
| Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Copanlisib, Niraparib - Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation | Phase 1 | Completed | M.D. Anderson Cancer Center | 31 | 2019-04-29 | 2026-07-23 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Anetumab Ravtansine, Bevacizumab, Paclitaxel - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 96 | 2018-10-12 | 2026-10-13 |
| Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) Birinapant, Carboplatin, Laboratory Biomarker Analysis - High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2018-08-01 | 2025-05-13 | |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, Bevacizumab, Computed Tomography - Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 444 | 2017-06-23 | 2026-10-26 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin, Paclitaxel, Ruxolitinib Phosphate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Completed | NRG Oncology | 147 | 2016-11-14 | 2025-05-25 |
| Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Adavosertib, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2016-02-04 | 2026-10-06 |
Fallopian Tube Neoplasms (10) · Ovarian Neoplasms (8) · Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Mucinous (1) · Adrenocortical Carcinoma (1) · Bile Duct Neoplasms (1) · Carcinoma (1) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Basal Cell (1) · Carcinoma, Endometrioid (1) · Carcinoma, Giant Cell (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1)
Adnexal Diseases (12) · Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Genital Diseases (12) · Genital Diseases, Female (12) · Genital Neoplasms, Female (12) · Neoplasms by Site (12) · Urogenital Diseases (12) · Urogenital Neoplasms (12) · Fallopian Tube Diseases (10) · Neoplasms (10) · Endocrine Gland Neoplasms (9) · Endocrine System Diseases (9) · Gonadal Disorders (9) · Ovarian Diseases (9)
Specimen Handling (5) · Magnetic Resonance Spectroscopy (4) · Bevacizumab (3) · Carboplatin (3) · Disulfides (3) · Immunoglobulin G (3) · Paclitaxel (3) · Taxes (3) · olaparib (3) · Biopsy (2) · Doxorubicin (2) · liposomal doxorubicin (2) · BAY 1895344 (1) · CTLA-4 Antigen (1) · Drug Therapy (1)
National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (3) · NRG Oncology (2) · Jonsson Comprehensive Cancer Center (1) · University of Washington (1)
United States (14) · Puerto Rico (2) · Canada (1) · Guam (1) · Japan (1)
Shannon N Westin (3) · Barbara Norquist, MD (1) · Charles N Landen (1) · James M Cleary (1) · Katherine C Fuh (1) · Rachel N Grisham (1) · Roisin E O'Cearbhaill (1) · Sanaz Memarzadeh (1) · Sandip P Patel (1) · Sarah F Adams (1) · Stephanie Lheureux (1) · Ying Liu (1)
PMID 32379297, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 37185961, PMID 38243705, PMID 38358334, PMID 38776484, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41528970, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
U10CA180868 (5), U10CA180888 (1), UM1CA186644 (1), UM1CA186691 (1), UM1CA186709 (1)